Search
Rumex crispus pollen
go.drugbank.com/drugs/DB10360ApprovedRumex crispus pollen is the pollen of the Rumex crispus plant. Rumex crispus pollen is mainly used in allergenic testing.
Mixtures: Number Two Weed MixtureErgosterol
go.drugbank.com/drugs/DB04038ApprovedWithdrawnA steroid of interest both because its biosynthesis in FUNGI is a target of ANTIFUNGAL AGENTS, notably AZOLES, and because when it is present in SKIN of animals, ULTRAVIOLET RAYS break a bond to result
Paclitaxel trevatide
go.drugbank.com/drugs/DB06171InvestigationalThree paclitaxel molecules linked by a cleavable succinyl ester linkage to a brain peptide vector, Angiopep-2, conjugate named ANG1005.
Synonyms: [a-N-(2'succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Thr-Glu-Glu-TyrLucinactant
go.drugbank.com/drugs/DB04897ApprovedIt contains sinapultide, a novel, hydrophobic, 21-amino acid peptide (leucine and lysine repeating units, KL4 peptide) designed to mimic human surfactant protein-B (SB-P).
Sabiporide
go.drugbank.com/drugs/DB21244ExperimentalThe usage of the INN stem '-poride' in the name indicates that Sabiporide is a Na+/H+ antiport inhibitor. Sabiporide has a monoisotopic molecular weight of 408.15 Da.
Gedatolisib
go.drugbank.com/drugs/DB11896ApprovedInvestigationalCelcuity describes gedatolisib as the first FDA-approved therapy to inhibit the pathway comprehensively across all class I PI3K isoforms and both mTOR complexes. … [L63927] Its approval also addresses a population defined by the absence of a biomarker, as patients with PIK3CA wild-type disease were not eligible for the PI3Kα-selective options.
Phosphoaminophosphonic acid guanylate ester
go.drugbank.com/drugs/DB02082ExperimentalA non-hydrolyzable analog of GTP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It binds tightly to G-protein in the presence of Mg2+.
Synonyms: Gpp(NH)pZebularine
go.drugbank.com/drugs/DB03068ExperimentalIt acts as a transition state analog inhibitor of cytidine deaminase by binding to the active site as covalent hydrates. … Also shown to inhibit DNA methylation and tumor growth both in vitro and in vivo.
Asciminib
go.drugbank.com/drugs/DB12597ApprovedInvestigational[L39005] It has also shown benefit in Ph+ CML with the T315I mutation, which produces a mutant BCR-ABL1 which is typically treatment-resistant as compared to wild-type BCR-ABL1.
XL281
go.drugbank.com/drugs/DB05190InvestigationalXL281 is a novel anticancer compound designed to potently inhibit the RAS/RAF/MEK/ERK signaling pathway. … XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which is activated in 60 percent of melanomas, 24-44 percent of thyroid cancers, and 9 percent of colon cancers.